Erasca (ERAS) Cash & Current Investments (2020 - 2026)

Erasca (ERAS) posted Cash & Current Investments of $243.8 million for Q1 2026, down 11.7% on a QoQ basis from $276.1 million in Q4 2025, and down 19.96% year-over-year from $304.6 million in Q1 2025.

Erasca (ERAS) Cash & Current Investments (2020 - 2026) Analysis & Trends

Erasca's Cash & Current Investments history runs 7 years deep, the most recent figure standing at $243.8 million for Q1 2026.

  • Quarterly Cash & Current Investments fell 19.96% year-over-year to $243.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $243.8 million (down 19.96% YoY) and the FY2025 annual result came in at $276.1 million, down 7.45% from the prior year.
  • Cash & Current Investments was $243.8 million for Q1 2026 at Erasca, down from $276.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $435.6 million in Q4 2022 and bottomed at $243.8 million in Q1 2026.
  • A 5-year average of $330.9 million and a median of $312.3 million in 2023 frame the typical range for Cash & Current Investments.
  • Annual changes were most pronounced in 2022 — Cash & Current Investments surged 130.92% — and 2023, when it fell 28.3%.
  • Erasca's Cash & Current Investments stood at $435.6 million in 2022, then declined by 28.3% to $312.3 million in 2023, then dropped by 4.5% to $298.3 million in 2024, then retreated by 7.45% to $276.1 million in 2025, then slipped by 11.7% to $243.8 million in 2026.
  • Business Quant data shows ERAS's Cash & Current Investments at $243.8 million in Q1 2026, $276.1 million in Q4 2025, and $288.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Oculis Holding AG 66,200.25 Bn 66,199.96 Bn - 283.54 Mn
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn - 61.40 Mn
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 471.75 Bn 466.96 Bn 1.35 Bn 4.79 Bn
5 Vertex Pharmaceuticals 121.94 Bn 114.69 Bn 2.59 Bn 7.25 Bn
6 Regeneron Pharmaceuticals 69.87 Bn 61.12 Bn 3.31 Bn 8.75 Bn
7 Belite Bio 62.43 Bn 62.43 Bn - -
8 Argenx Se 55.86 Bn 50.68 Bn 1.41 Bn 5.18 Bn
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn 3.01 Bn
10 Erasca 5.81 Bn 5.57 Bn - 243.79 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 243.79 Mn
Dec 31, 2025 276.08 Mn
Sep 30, 2025 288.40 Mn
Jun 30, 2025 300.66 Mn
Mar 31, 2025 304.59 Mn
Dec 31, 2024 298.31 Mn
Sep 30, 2024 318.91 Mn
Jun 30, 2024 408.41 Mn
Mar 31, 2024 393.76 Mn
Dec 31, 2023 312.35 Mn
Sep 30, 2023 296.67 Mn
Jun 30, 2023 317.25 Mn
Mar 31, 2023 389.74 Mn
Dec 31, 2022 435.62 Mn
Sep 30, 2022 355.93 Mn
Jun 30, 2022 292.73 Mn
Mar 31, 2022 392.53 Mn
Dec 31, 2021 414.48 Mn
Sep 30, 2021 486.65 Mn
Jun 30, 2021 193.67 Mn